Base-case results and PSA (United States health care perspective)
| Strategy . | Cost (95% CI) (USD) . | Incremental cost (95% CI) (USD) . | Effectiveness (95% CI) (QALY) . | Incremental effectiveness (95% CI) (QALY) . | INMB (95% CI) (USD/QALY) . | % Cost-effectiveness at WTP threshold of $50 000 . | % Cost-effectiveness at WTP threshold of $100 000 . | % Cost-effectiveness at WTP threshold of $150 000 . |
|---|---|---|---|---|---|---|---|---|
| United States model (lifetime horizon) | ||||||||
| Upfront HSCT | $1 645 900 ($1 435 600-$1 869 900) | $371 100 ($227 300-$482 100) | 9.74 (8.75-10.72) | 0.84 (−0.39 to 2.16) | $497 100 ($259 800-$719 600) | 100 | 100 | 100 |
| Delayed HSCT | $2 017 000 ($1 790 900-$2 236 600) | 8.90 (8.01-9.70) | 0 | 0 | 0 | |||
| INMB at thresholds of $50 000, $100 000, and $150 000 per QALY (95% CI) $413 100 ($248 600-$542 200), $455 100 ($262 200-$620 700), and $497 100 ($259 800-$719 600) | ||||||||
| United States model (10-year horizon) | ||||||||
| Upfront HSCT | $1 589 000 ($1 379 700-$1 813 000) | $132 900 (–$13 400 to $224 800) | 4.74 (4.41-5.09) | 0.30 (−0.18 to 0.82) | $178 000 ($13 400-$298 800) | 97.51 | 98.23 | 98.43 |
| Delayed HSCT | $1 722 000 ($1 484 200-$1 927 400) | 4.44 (4.01-4.83) | 2.49 | 1.77 | 1.57 | |||
| INMB at thresholds of $50 000, $100 000, and $150 000 per QALY (95% CI) $147 900 (−$7200 to $252 400), $162 900 (−$4000 to $272 500), and $178 000 ($13 400-$298 800) | ||||||||
| Strategy . | Cost (95% CI) (USD) . | Incremental cost (95% CI) (USD) . | Effectiveness (95% CI) (QALY) . | Incremental effectiveness (95% CI) (QALY) . | INMB (95% CI) (USD/QALY) . | % Cost-effectiveness at WTP threshold of $50 000 . | % Cost-effectiveness at WTP threshold of $100 000 . | % Cost-effectiveness at WTP threshold of $150 000 . |
|---|---|---|---|---|---|---|---|---|
| United States model (lifetime horizon) | ||||||||
| Upfront HSCT | $1 645 900 ($1 435 600-$1 869 900) | $371 100 ($227 300-$482 100) | 9.74 (8.75-10.72) | 0.84 (−0.39 to 2.16) | $497 100 ($259 800-$719 600) | 100 | 100 | 100 |
| Delayed HSCT | $2 017 000 ($1 790 900-$2 236 600) | 8.90 (8.01-9.70) | 0 | 0 | 0 | |||
| INMB at thresholds of $50 000, $100 000, and $150 000 per QALY (95% CI) $413 100 ($248 600-$542 200), $455 100 ($262 200-$620 700), and $497 100 ($259 800-$719 600) | ||||||||
| United States model (10-year horizon) | ||||||||
| Upfront HSCT | $1 589 000 ($1 379 700-$1 813 000) | $132 900 (–$13 400 to $224 800) | 4.74 (4.41-5.09) | 0.30 (−0.18 to 0.82) | $178 000 ($13 400-$298 800) | 97.51 | 98.23 | 98.43 |
| Delayed HSCT | $1 722 000 ($1 484 200-$1 927 400) | 4.44 (4.01-4.83) | 2.49 | 1.77 | 1.57 | |||
| INMB at thresholds of $50 000, $100 000, and $150 000 per QALY (95% CI) $147 900 (−$7200 to $252 400), $162 900 (−$4000 to $272 500), and $178 000 ($13 400-$298 800) | ||||||||
Costs have been rounded to the nearest hundred.
USD, United States Dollar.